Publication
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugPertuzumabcivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneERBB2civic_curation1.00
- geneERBB3civic_curation1.00
- variantERBB2 Amplificationcivic_curation1.00
- variantERBB2 Mutationcivic_curation1.00
- variantERBB3 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36315917
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Amplification1 | ||||||||
| Pertuzumab + TrastuzumabCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID11668In this clinical study of 38 patients with colorectal cancer (CRC), 28 had CRC with ERBB2 amplification, and were treated with a combination of Pertuzumab and Trastuzumab. The DC rate in the patients … (full text at CIViC) PMID 36315917 · Gupta et al., 2022 · Open in CIViC | civic |
| ERBB2 Mutation + ERBB3 MutationERBB3ERBB21 | ||||||||
| Pertuzumab + TrastuzumabCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID11669In this clinical study of 38 patients with colorectal cancer (CRC), 10 had CRC with ERBB2/ERBB3 mutation, and were treated with a combination of Pertuzumab and Trastuzumab. A DC of 10% and OR of 0% we… (full text at CIViC) PMID 36315917 · Gupta et al., 2022 · Open in CIViC | civic |